|
|
|
|
Growth in CVD drug usage to help generics
Big pharmaceutical companies will struggle to profit from the expanding cardiovascular disease market over the next decade despite growing drug usage, according to Datamonitor.New research by the independent business analyst predicts the CVD pharmaceuticals...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
'Two key treatments do not halt diabetes in people with early signs of the disease,' BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
2 Drugs Fail to Prevent Diabetes in the Overweight
SUNDAY, March 14 (HealthDay News) -- Hopes that two available drugs could help prevent diabetes and the problems it causes in overweight people with poor sugar metabolism have been dashed by a major international study.The trial involved two drugs prescribed...
|
|
|
ARB 'cuts diabetes risk in IGT patients'
Stephen Robinson, GP newspaper, Valsartan reduces the risk of people with impaired glucose tolerance (IGT) developing diabetes, a US study suggests.Participants undertook a lifestyle intervention programme Researchers studied patients with IGT, as well...
|
|
|
ARB 'cuts diabetes risk in IGT patients'
Stephen Robinson, GP newspaper, Valsartan reduces the risk of people with impaired glucose tolerance (IGT) developing diabetes, a US study suggests.Participants undertook a lifestyle intervention programme Researchers studied patients with IGT, as well...
|
|
|
Drugs for halting diabetes tested
'Two key treatments do not halt diabetes in people with early signs of the disease,' BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Dual Action Drug Fights High Blood Pressure, Heart Disease
(Ivanhoe Newswire) -- A new dual-action drug, called LCZ696, is well tolerated and provides significantly greater reductions in blood pressure than the established angiotensin receptor blocker (ARB) valsartan.LCZ696 might be superior to standard ARBs...
|
|
|
Drugs for halting diabetes tested 'Two key treatments do not halt diabetes in people with early signs of the d
'Two key treatments do not halt diabetes in people with early signs of the disease,' BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Two diabetes drugs fail to help high-risk patients
Digg Facebook StumbleUpon Delicious E-Mail to a Friend ATLANTA (Reuters) - The Novartis diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease,...
|
|
|
Novartis reports positive results from valsartan diabetes study
You are trying to open a news article from our archive.In order to read this article you need to login with your username and password. Novartis reports positive results from valsartan diabetes study.
|
|
|
Novartis Pharma AG (NVS) Reports Positive Results From Phase II LCZ6
Novartis Pharma has reported that its investigational product LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), has successfully completed its first large-scale clinical trial, highlighting the potential of the compound in the treatment of...
|
|
|
NAVIGATOR trial shows valsartan delayed progression to type 2 diabetes in cardiovascular patients
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
|
|
Drugs for halting diabetes tested
"Two key treatments do not halt diabetes in people with early signs of the disease," BBC News reported.The story is based on a large trial assessing the effects of two approved diabetes medications, valsartan and nateglinide, on the development of...
|
